In compliance with current regulations, let us know which audience you belong to:
Meibomask® is our answer to professionals that want to focus on the unique benefits of our LM® LLLT technology for the treatment of most ocular surface diseases.
Built with the same industrial design of our other solutions, meibomask® packs a punch when it comes to photobiomodulation technology—enabling patients and operators to benefit from everything Light Modulation® Low Level Light Therapy (LM® LLLT) has to offer:
COMPLETE + DIRECT TREATMENT
meibomask® enables a full therapy, covering both lower and upper eyelids, to grant maximum efficacy in treating Dry Eye Disease (DED) induced by Meibomian Glands Dysfunction (MGD), Chalazion, Blepharitis, Sjögren’s Syndrome, Post-blepharoplasty.
meibomask® and LM® LLLT provide patients with an entirely painless therapy. Near-infrared light is emitted on the skin at a medically-certified wavelength, generating endogenous heating by stimulating cells’ ATP production.
QUICK + EASY
For patients, this means immediate relief, just 15’ after the therapy—for operators, it means delivering greater value to patients, with much less effort.
No training needed, no set-up time. It just works.
Our patented photobiomodulation technology solicits cells’ mitochondria, triggering biochemical and biophysical reactions that stimulate them to a better protein synthesis. Thanks to the near-infrared emission of light, the tear lipid layer is increased and stabilized.
meibomask® provides patients with custom treatments based on the MGD severity level detected with me-check® screening. According to the severity of meibomian glands loss, meibomask® releases the correct amount of energy and treatment duration for every specific patient.
Prof. Roberto Bellucci shares his experience of tapping into the Espansione Ecosystem to treat ocular surface disease through our meibomask® solution, powered by LM® LLLT technology.